Global Gastric Cancer Diagnostic Market Size study, by Product by Disease Type, by End User and Regional Forecasts 2022-2032

Description

Global Gastric Cancer Diagnostic Market is valued approximately at USD 2.42 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.32% over the forecast period 2024-2032. Gastric cancer diagnostic encompasses a series of medical procedures, tests, and evaluations conducted by healthcare professionals to detect and confirm the presence of gastric cancer, also known as stomach cancer. These diagnostic methods include imaging studies, endoscopic examinations, biopsy, blood tests, and molecular profiling. The primary aim of gastric cancer diagnostics is to identify the disease at an early stage, accurately evaluate its extent and severity, and guide subsequent treatment decisions. Early diagnosis is critical, as it significantly impacts patient outcomes by enabling timely intervention and appropriate treatment.

The growth of the gastric cancer diagnostic market is propelled by an increase in rising incidences of gastric cancer and a surge in demand for advanced diagnostic tools for treatment. The rising prevalence of gastric cancer globally leads to a heightened need for diagnostic services, driving market expansion. Additionally, continuous technological advancements in endoscopy, molecular testing, and imaging techniques enhance the accuracy and efficiency of gastric cancer diagnosis, further fueling market growth. Moreover, increasing awareness about the importance of early diagnosis and the availability of gastric cancer diagnostic tools are driving forces in enhancing public health and cancer care. This growing awareness helps individuals understand the significance of early detection in combating gastric cancer, a disease that often remains asymptomatic until advanced stages, thus fueling market growth. However, the high cost of diagnostic tests can deter individuals from seeking early diagnosis, especially in regions with limited access to affordable healthcare, negatively impacting market growth. Concerns about financial burden may lead patients to postpone or avoid diagnostic tests, resulting in delayed diagnosis and more advanced disease stages at the time of diagnosis, thereby restraining market expansion.

The key regions considered for the Global Gastric Cancer Diagnostic Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America dominated the market in revenue attributed to its advanced healthcare infrastructure, higher incidence rates, extensive screening programs, focus on precision medicine, and a growing aging population. The presence of major players such as Abbott Laboratories, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., and Agilent Technologies, Inc., also contributes to market growth in the region. Furthermore, the Asia-Pacific region is expected to grow at the highest rate during the forecast period.

Major market players included in this report are:

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Agilent Technologies, Inc.
Fulgent Genetics
Exact Sciences Corporation
MiRXES Pte Ltd
Bio-Rad Laboratories, Inc.
Hipro Biotechnology Co., Ltd.
Endofotonics Pte Ltd
Qiagen NV
PerkinElmer, Inc.
Thermo Fisher Scientific Inc.
Becton, Dickinson and Company
Siemens Healthineers AG
Illumina, Inc.

The detailed segments and sub-segment of the market are explained below:

By Product:

Reagents and Consumables
Instruments

By Disease Type:

Adenocarcinoma
Gastric Lymphoma
Others

By End User:

Hospitals
Diagnostic Laboratories
Diagnostic Imaging Centers

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

Chapter 1. Global Gastric Cancer Diagnostic Market Executive Summary

1.1. Global Gastric Cancer Diagnostic Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Product
- 1.3.2. By Disease Type
- 1.3.3. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Gastric Cancer Diagnostic Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Gastric Cancer Diagnostic Market Dynamics

3.1. Market Drivers
- 3.1.1. Increasing Incidences of Gastric Cancer
- 3.1.2. Technological Advancements in Diagnostics
- 3.1.3. Growing Geriatric Population
3.2. Market Challenges
- 3.2.1. High Cost of Diagnostic Tests
- 3.2.2. Limited Access to Healthcare in Some Regions
3.3. Market Opportunities
- 3.3.1. Growing Awareness of Early Diagnosis
- 3.3.2. Expansion into Emerging Markets
- 3.3.3. Increased Focus on Precision Medicine

Chapter 4. Global Gastric Cancer Diagnostic Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Gastric Cancer Diagnostic Market Size & Forecasts by Product 2022-2032

5.1. Segment Dashboard
5.2. Global Gastric Cancer Diagnostic Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Reagents and Consumables
- 5.2.2. Instruments

Chapter 6. Global Gastric Cancer Diagnostic Market Size & Forecasts by Disease Type 2022-2032

6.1. Segment Dashboard
6.2. Global Gastric Cancer Diagnostic Market: Disease Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Adenocarcinoma
- 6.2.2. Gastric Lymphoma
- 6.2.3. Others

Chapter 7. Global Gastric Cancer Diagnostic Market Size & Forecasts by End User 2022-2032

7.1. Segment Dashboard
7.2. Global Gastric Cancer Diagnostic Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospitals
- 7.2.2. Diagnostic Laboratories
- 7.2.3. Diagnostic Imaging Centers

Chapter 8. Global Gastric Cancer Diagnostic Market Size & Forecasts by Region 2022-2032

8.1. North America Gastric Cancer Diagnostic Market
- 8.1.1. U.S. Gastric Cancer Diagnostic Market
  - 8.1.1.1. Product breakdown size & forecasts, 2022-2032
  - 8.1.1.2. Disease Type breakdown size & forecasts, 2022-2032
  - 8.1.1.3. End User breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Gastric Cancer Diagnostic Market
8.2. Europe Gastric Cancer Diagnostic Market
- 8.2.1. U.K. Gastric Cancer Diagnostic Market
- 8.2.2. Germany Gastric Cancer Diagnostic Market
- 8.2.3. France Gastric Cancer Diagnostic Market
- 8.2.4. Spain Gastric Cancer Diagnostic Market
- 8.2.5. Italy Gastric Cancer Diagnostic Market
- 8.2.6. Rest of Europe Gastric Cancer Diagnostic Market
8.3. Asia-Pacific Gastric Cancer Diagnostic Market
- 8.3.1. China Gastric Cancer Diagnostic Market
- 8.3.2. India Gastric Cancer Diagnostic Market
- 8.3.3. Japan Gastric Cancer Diagnostic Market
- 8.3.4. Australia Gastric Cancer Diagnostic Market
- 8.3.5. South Korea Gastric Cancer Diagnostic Market
- 8.3.6. Rest of Asia Pacific Gastric Cancer Diagnostic Market
8.4. Latin America Gastric Cancer Diagnostic Market
- 8.4.1. Brazil Gastric Cancer Diagnostic Market
- 8.4.2. Mexico Gastric Cancer Diagnostic Market
- 8.4.3. Rest of Latin America Gastric Cancer Diagnostic Market
8.5. Middle East & Africa Gastric Cancer Diagnostic Market
- 8.5.1. Saudi Arabia Gastric Cancer Diagnostic Market
- 8.5.2. South Africa Gastric Cancer Diagnostic Market
- 8.5.3. Rest of Middle East & Africa Gastric Cancer Diagnostic Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. F. Hoffmann-La Roche Ltd
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Abbott Laboratories
- 9.3.3. Agilent Technologies, Inc.
- 9.3.4. Fulgent Genetics
- 9.3.5. Exact Sciences Corporation
- 9.3.6. MiRXES Pte Ltd
- 9.3.7. Bio-Rad Laboratories, Inc.
- 9.3.8. Hipro Biotechnology Co., Ltd.
- 9.3.9. Endofotonics Pte Ltd
- 9.3.10. Qiagen NV
- 9.3.11. PerkinElmer, Inc.
- 9.3.12. Thermo Fisher Scientific Inc.
- 9.3.13. Becton, Dickinson and Company
- 9.3.14. Siemens Healthineers AG
- 9.3.15. Illumina, Inc.

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes